OTIC News and Press, Otonomy Inc. From 07/18/22

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference)....

The following slide deck was published by Otonomy, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Otonomy, Inc. 2022 Q1 - Results - Earnings Call Presentation

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene &...

Otonomy, Inc. (OTIC) Q1 2022 Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Robert Uhl - IR David Weber - President, CEO and Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Ken Cacciatore - Cowen Chris Raymond - Piper Sandler P...

Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q1 2022 Earnings Call May 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q1 2022 Earnings Call Transcript

Otonomy press release (NASDAQ:OTIC): Q1 GAAP EPS of -$0.20. Cash, cash equivalents, and short-term investments totaled $62.9 million as of March 31, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Otonomy expects that GAAP operating expenses will be in the range of $52-...

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluation OTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilatera...

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4...